Reddit Posts
Mentions
ATYR. High risk high potential reward. Phase 3 readout pending. Bull or bear, one side will win
I have $2k use Robinhood. It’s enough for small to mid cap. I have LVL 2 trading. I also have a watch list of 40 potential stocks. Before I place a trade I pick a few my price range and see what will give me the best premiums vs the cost. Some stocks are riskier than others like ATYR. It’s a pharma play based on upcoming phase 3 trial results. Which come out this month
True look at OPEN today. I was able to sell all but 100 shares for a very small profit. I’m keeping the last 100 shares for a CC tomorrow also have a $5.50 CSP on Open. Also have 4 $4.00 CSP on ATYR expiring next week. Playing on their Phase 3 trial results. But the premiums are juicy. I’m averaging about $138 a contract. Both are risky short term plays. So we all have been there. In hindsight always learn from bad trades and never deviate from your plan. It can bit ya in the butt
Can you explain why ATYR?
ATYR has some juicy premiums for 19Sep expiration. >30% roi with a delta of 0.2 for csp They have some trial results coming next week I think so it could tank
I have one $5.50 CSP on OPEN. I’ve made a lot of money with CSP on that stock. And 2 $4CSP on ATYR. Expiring next week, which so far it looks like all 3 are going to expire worthless.
ATYR phase 3 data may come out this week. Super risky binary event, proceed with cautioh I’m long 280 shares
ATYR for me...these next 2 weeks gonna be juicy
If you’re such a superstar and not a con artist or scammer then why do you need to ask about ATYR from common people 🤔🤔
ATYR's binary event may happen this week. All estimates agree that it either goes to $1 (cash value) or 3-4x. All based off the top line results readout. Shorts include many experts like Martin Shkreli. Longs include all of r/CountryDumb and r/ATYR_Alpha. Been a hell of a ride. Buckle up folks.
FWIW, all the smart folks on biotech X are big time short ATYR. The guys with ports up like 10x over the past year. Do some digging. Efzo is not a good drug. Or a drug at all.
Try some OCT ATYR up or down- it'll be a fun ride for us! Lots of vol, lots of prem!!
Nice TLDR. Couldn’t have said it much better. Don’t forget this isn’t their only drug as well. There’s a lot more in the pipeline As a high schooler, I hope ATYR can pay for my college education
I pick allot of companies. Pick 2 or 3. Look up the financials. Any current news reports. Then I look at the 1week, 1,month, and 3 month charts. I don’t look at moving avg lines or any bands, just a naked chart and look for a consistent graph. If I like what I see. I will then see if they have weekly options. Then place weekly CSP’s. With a .3-.2 delta. Which is a conservative delta I think. The are OTM and can have decent premiums. My current plays are on OPEN and ATYR.
I have a few hundred shares in ATYR, nothing to crazy. I am excited for phase 3 readout!
ATYR has phase 3 trial results in the next 2 weeks. Good chance of approval. User Better-Ad has done some very nice DD’s.
I know ATYR is not on there as its over the $5. I remember it having a POA of 65% last month. I was wondering if it changed since last time. Do you think you could share the current stats on ATYR?
Nice explanation, I own 35K shares with 100% protfolio on ATYR. As per your guess on positive readout what will be the stock price after positive readout?
ATYR, ACHV, CLRB, -- gamble NWBO
Note: this 100% gamble. proceed with caution. I'm 280 shares long on ATYR. Their phase 3 readout should come any day now. It is a binary event so proceed with caution but I have confidence it'll work out based on what i've seen. Check out r/ATYR_Alpha they do some really good objective DD
Yeaa!! I see price targets are 27!! I can’t find a community for ATYR tho
ATYR, MBOT, CRNX. Thank me later.
Technical analysis is a dark art of negligible value when it comes to setups such as ATYR, so close to catalyst. Prove me wrong.
With a small account on Robinhood, weekly CSP’s on small cap stocks with an IV of around 90-200, a popular one right now is OPEN. It’s a steady CSP money maker with CSP’s or 30-45,day call options. The puts are losing trades on open. If your really ballsy ATYR $4 CSP at a IV of 643% or the $3CSP with An IV of 680% both expiring on the 19 of this month, these are just a few popular plays right now. Both stocks will make you money. But it’s a slow climb
I genually feel bad for ininformed and overleveraged ATYR bulls. The stock is likely a 0 and they have no clue.
I don't think you will get this at $4.36 as I know I'm not selling a share -- this dude is funny he calls the study rigged to win I love it -- See this post [https://stocktwits.com/dewmoore/message/627707925](https://stocktwits.com/dewmoore/message/627707925) \+ see also he went deep on why wells fargo says it could go higher than $25 possibly $58 plus SEE this too -- [https://stocktwits.com/dewmoore/message/627649320](https://stocktwits.com/dewmoore/message/627649320) I read all but he sort of breaks it down so that the little people understand lol plus I read the other guy here on reddit r/ATYR_Alpha now his is DEEP and lots of reading but worth it -- but if you don't wanna read all of that read the other guy pretty good and he gives us his sources too GLTY
Looks like the expiration in 14 days This is the shares + options https://optionstrat.com/build/collar/ATYR/ATYRx100@5.39,.ATYR250919P7,-.ATYR250919C8 this is just the options https://optionstrat.com/build/short-combo/ATYR/.ATYR250919P7,-.ATYR250919C8
Martin seems like a nutjob to me when watching him on youtube. r/ATYR_Alpha analysis on reddit seems very logical.
Myself a 5.50CSP on Opendoor. Plus I own 200 shares. Also 2 $4 CSP on ATYR. That expires on the 19th. Right now both are sitting pretty.
Good potential with ATYR indeed.
anybody have ATYR? what do you guys think about the stock?
ATYR phase 3 announcement in 6-14 days. It either falls 80% or rises 200-400%
These stocks have catalysts in September to October. September 8-10, 2025 (4-6 days from now): • PSTV (Plus Therapeutics, $0.43): Presentation at H.C. Wainwright 27th Annual Global Investment Conference (September 8-10). Likely to highlight progress on CNSide, a cerebrospinal fluid diagnostic platform for detecting and managing central nervous system cancers (e.g., leptomeningeal metastases, ~$6B market). Positive data or partnership updates could drive 20-50% upside (~$0.52-0.65), based on historical conference-driven moves in micro-cap biotechs. Q3 2025 (by September 30) may also include updates on CNSide’s commercial launch or ReSPECT-GBM trial (rhenium-186 obisbemeda for glioblastoma), potentially adding 10-30% upside (~$0.47-0.56). Risk: Limited cash runway (~$8M market cap) and trial delays. • September 10-17, 2025 (6-13 days): • ATYR (aTyr Pharma, $5.44): Topline data from Phase 3 EFZO-FIT study for efzofitimod in pulmonary sarcoidosis (~200K US patients, no approved therapies). The largest-ever sarcoidosis trial (268 patients, 85 sites, 9 countries) tests steroid-sparing effects (primary endpoint: OCS dose reduction by week 48) and secondary endpoints (lung function, symptoms). Positive results could yield 200-400%+ upside ($16.32-27.20, ~$4406-7344 on 270 shares), potentially hitting your ~$5,000 goal at ~260% ($19.39, ~$5235). Negative results risk a ~50% drop (~$734). Confidence: 60-70%, based on Phase 1b/2a (58% steroid reduction, improved FVC), four positive DSMB reviews, and analyst Buy ratings ($17-35 targets). A late-breaker presentation at the European Respiratory Society (ERS) Congress (September 30, 2025, ALERT 3 session) may amplify visibility post-readout. • Throughout September 2025 (1-26 days): • NRXP (NRx Pharmaceuticals, $2.60): Ongoing rollout of HOPE Therapeutics, including a flagship location in Palm Beach and advancement of ketamine-based treatments (NRX-100) for bipolar depression and suicidality (FDA Fast Track). No specific date, but updates on commercialization or trial progress could drive 10-30% upside (~$2.86-3.38). Less binary than ATYR’s data, but sentiment boosts possible given mental health market interest. Risk: Execution delays, funding needs (~$52M market cap). • September 29, 2025 (~25 days): • IXHL (Incannex Healthcare, $0.66): Q2 or interim earnings report, potentially updating on cannabinoid/psychedelics trials (e.g., PsiGAD for anxiety, IHL-42X for sleep apnea). Positive trial updates could drive 10-30% upside (~$0.73-0.86), though earnings alone are less impactful unless paired with clinical milestones. Risk: Limited analyst coverage, high volatility (~$28M market cap). • September 30, 2025 (~26 days): • FBIO (Fortress Biotech, $2.58): FDA PDUFA decision for CUTX-101 (copper histidinate) for Menkes disease, a rare genetic disorder (~1 in 100,000-300,000 male births). Priority Review, Breakthrough Therapy, Fast Track, and Orphan Drug designations signal strong data (80% mortality reduction, median survival 177.1 vs. 16.1 months). Approval could yield a Priority Review Voucher ($100M+ value) and 50-150%+ upside (~$3.87-6.45). Denial risks a sharp drop. Additional visibility from H.C. Wainwright conference (on-demand from September 5). • MBOT (Microbot Medical, ~$3.13): FDA 510(k) clearance decision for LIBERTY Endovascular Robotic System, expected by Q3 end (September 30). Pivotal ACCESS-PVI trial showed 100% navigation success, 92% radiation reduction, and no adverse events. Approval could drive 100-200%+ upside (~$6.26-9.39, based on $9 analyst target), enabling Q4 2025 commercialization. Denial risks a ~50% drop. Recent executive hires and $630K grant add sentiment. Risk: Regulatory uncertainty (~$20-30M market cap). • NVNI (Nvni Group, $0.586): H1 2025 earnings and investor webinar, with potential 1-2 acquisition closes by Q3 end. Strong revenue or AI/acquisition updates could drive 10-30% upside (~$0.64-0.76). Risk: Micro-cap illiquidity, Nasdaq compliance issues (~$21M market cap). • No Specific September Catalysts: • ONDS (Ondas Holdings, ~$5.46): Recent stock offering (August 2025) and drone tech growth updates, but no confirmed September events. Q3 earnings (likely October-November) could drive 10-20% (~$5.57-6.55). Risk: Recent downside forecasts (-12% analyst target). • AIRE (reAlpha Tech, ~$0.39): Possible conference (e.g., H.C. Wainwright, not confirmed), but no specific catalyst. Q2 earnings (August 2025) showed 1909% revenue growth, but dilutions cap upside (10-20%, ~$0.43-0.47). Risk: High short interest, compliance issues. • IBRX (ImmunityBio, ~$2.34): No September-specific events. Anktiva (immunotherapy) launch updates or H2 2025 data (e.g., bladder cancer trials) could drive 20-50% (~$2.81-3.51). Risk: Debt, larger cap (~$1.6B) tempers volatility.
Has anyone here starting looking at ATYR - I know it’s biotech but there’s a lot to sit up and listen about with this play
i also sold CC on ATYR. What is your CSP strike? I don't know if there is a longterm purpose of holding ATYR if the results turn out bad so Im curious to hear your strike and if youre willing to hold longterm
ATYR. Has their phase 3 trial results coming out later this month. That will make it brake them. I have a CC and a CSP on them. If it goes up I make money off it goes down the same. Even if it stays flat. ASST I have a CSP on them.
Fellow ATYR bro, 500 shares for ATYR to the moon!
Same lol I've been burned by biotech in the past. ATYR seems to be playing the right moves with patents and future expansion beyond pulmonary sarcoidosis but it's all make or break with these phase III results. It's my Q3 moonshot play, we'll see!
ATYR. Been watching this one a minute and it looks like it’s ready to pop. Probably will buy shares not options though. Big news expected mode September
Sold a shitload of ATYR puts because I’m an idiot. Premium is insane though. 4 dollar put had a breakeven of 2.50
Lol, well let's see what your logic is and we'll discuss it. Martins entire argument is from a 2022 document, he never includes that information in his rants about ATYR. Quite literally, his entire argument is 3 years old, he's praying on people's inability to research his argument themselves and assuming people will trust him on blind allegiance because the data he's quoting is "overly complicated" aka he's copy and pasting information directly from a 2022 document on ATYR's website. Do you have a different argument or just sticking to calling everyone "retards" - because you quite literally struggle with formulating a basic sentence maybe you're one of those blind followers.
ATYR squeeze is starting today!
ATYR squeeze starting today
ATYR phase 3 this month! This could be a monster.
ATYR is a pharmaceutical company that has a big development coming in about a month. The result of that development will either cause the stock to crash or quadruple. It’s a risky play even if you have advanced insight into the field. I bought shares that I sold covered calls on which reduces my risk exposure significantly while still giving me the potential to double my money. Double my money or lose 30%, acceptable risk/reward to me.
So, whose gambling on ATYR this month?
Love readings Tweedles write up too on ATYR
https://www.reddit.com/r/ATYR_Alpha/s/pFYmG4rhvh Check out this guys reports. Also another Reddit guy named CountryDumb
Could you add $ATYR on that please?
https://www.reddit.com/r/ATYR_Alpha/s/ySowlWs1DY Sorry I capped alpha. It’s a subreddit dedicated to ATYR the stock and its research. The best D&d you’ll ever get surrounding a stock without paying
https://www.reddit.com/r/ATYR_Alpha/s/ySowlWs1DY Sorry I capped alpha. It’s a subreddit dedicated to ATYR the stock and its research. The best D&d you’ll ever get surrounding a stock without paying
ATYR hasn’t been under mid $4 since April.
Check out ATYR_ALPHA. This is going to be huge. They scheduled an LBA at the ERS in Australia. This spot is literally reserved for top line game changing data. And the ERS is the GLOBAL gold standard. It’s biotech so definitely could fail but I am holding around 3k shares and really excited about this potential.
ATYR believes that by pushing down inflammatory signals, that there will be a reduction in the granulomas and fibrotic tissue in patients. But pretty much everything that has been tried in this indication has failed, including many of the drugs that directly lower key cytokines in the inflammatory cascade.
Sell cash secured put on ATYR
Is that a long ATYR position 😥
Damn you’re really blindly following the ATYR bag holders hahaha
I’m the opposite: full port on ATYR with $860k. In three weeks, my liquid net worth will either jump 5x or drop by 80%. No in between.
But 100 shares of ATYR immediately
Sold some ATYR $6 9/19 calls for $2.35. Feeling like a genius.
Off topic, but any data on ATYR?
Approval to my understanding requires a Phase 3 trial. ATYR has not been granted anything, I think the stock will 80/20 fail/success. We will see very soon.
My cash was already tied up in other plays and entering late just felt like FOMO, congrats on timing it though! And yeah that's true, most of them are just ChatGPT pumps. That being said I did find out about ATYR and MBOT in this sub. Entered late but I'm hopeful for the upcoming catalysts. CGTX also would've been a nice play if I had the money to enter a few weeks ago.
I scooped up 3 biotechs because I heard about INSM talk, looked it up, chat gpt’d the heck out of it and yup …. Safest play out there in its field and still a long runway ahead. I set aside an account biotech portion, so 50% INSM and I love the next two more but the are risky - but 500x/1000x potential: NRXP and ATYR. Just talks a look, I think these hidden gems are worth it and can catch a dip after the market yesterday.
I’ll thro two more “boom than bust” biotechs getting some early attention: NRXP, ATYR Full disclosure I own INSM as my safe biotech play and plan to split what’s left in my account between the top 2 mentioned just to dip a toe in a possible 250x-1000x pool. G’luck all :) https://preview.redd.it/yoinhmyplyjf1.jpeg?width=1284&format=pjpg&auto=webp&s=30d9cf0a54b2a97123dcb5f3b8c62390e1e15d40
I'm new to this. Hear me out, the word BioTech appears and you run for the hills. But this time its different (probably not - I'm coping). I saw a post recently about aTyr Pharma (ATYR) and decided to put my reservations behind me and take a look. Of the 6 analyst ratings I found, all of them were a BUY, with the average of the price targets projecting a return of \~300%, the highest at 600%, a man can dream... Was my days worth of research just confirmation bias, quite possibly, or it could just be the fact that analysts seem to have no issue with risk, just the potential upside (its not their money after all). Last patient visit completed in Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis (don't worry its a drug for something bad to do with the lungs); topline results expected in mid-September 2025 (BIG CATALYST FINGERS CROSSED). Their results from Phase 1 and 2 testing look promising (I don't really know I'm not a scientist). Their drug is the only one of its kind = no competitors if they get FDA approval = $$$ = stock price rips (in my dreams). Not only that, but the potential for a short squeeze is HUGE, which people of this subreddit seem to enjoy. A reasonably small float + VERY high short interest (\~25% of the float) = serious potential. What am I gonna do about it? Not much. I'm not rich, otherwise i wouldn't be doing this. But I've bought 100 shares of the stock which is going to go ahead and be more than I'm willing to lose. Why no options? IV is at a ridiculous all time high of nearly 400 - thats the market pricing in a 25% move by AYTR stock everyday for the next month - probably not. The premiums on these bad boys are therefore costing the same as my mortgage. If anything, it leaves me tempted to sell the furthest out $12C - at least then if this all goes wrong and it tanks ill have some premium to help cry myself to sleep. At the end of the day DYOR, I've not really got a clue whats going on, I'm just feeding a semi-functional gambling addiction mixed with cripling ADHD. This can in no way be classified as financial advice, I just like the look of this stock in the same way that I do the food in the fridge when I've had a couple beers. Till next time
Check ATYR out, high shirt interest, big players involved (Martin Shkreli and co shorting it), big binary event coming up with either a 4x (analysts estimate average) or a 90% drop. Not saying which way it will go as I would have no idea, but it's a classic short squeeze build up play
Thanks. I think you are in a very good position. I have been in and out of ATYR which has a drug waiting for the 3rd stage results this September. Fidelity charges $50 for buying and selling it again. However, it is on my watchlist and again on my screen at the 8th position out of 8 charts..
I have RZLV and ATYR currently of those. Considered WULF but already have plenty of exposure in that space
He's currently shorting the hell out of ATYR too
aTyr Pharma (ATYR) could become a 8-10x stock in the coming months due to its upcoming Phase 3 clinical trial results for its lead drug candidate, efzofitimod. The drug aims to treat pulmonary sarcoidosis, a serious lung disease with a massive unmet market need. Positive results from the Phase 3 trial would be a transformative event for the company, as a successful Phase 3 is often the biggest catalyst for a biotech stock. This would validate their entire scientific platform and could lead to a significant re-rating of the stock.
$BTAI * Inputs: fragile revenue, expensive trials, AI hype. * Process: clinical data → investor sentiment swing. * Output: binary price dynamics: explosive if positive trial outcomes; implosion if not. **Concise Verdict:** * **Structural posture:** High-risk speculative biotech. Upside only plausible with robust Phase 3 success or FDA progress. * **Action Guidance:** Suitable only for speculative trading or watchlist. If one positions, tight risk control essential. $ATYR * Inputs: negligible current revenue, early clinical pipeline. * Process: trial outcomes → speculation cycles. * Output: price swings contingent on success signals; structural instability persists until proof of efficacy. **Concise Verdict:** * **Structural posture:** High-risk clinical development. Potential upside with positive data, but execution risk high. * **Action Guidance:** View as speculative watchlist candidate. Allocate only if monitoring trial progress and financing clarity. **$MDAI** * Inputs: device validation progress, funding, regulatory tensions. * Process: signaling through filings and FDA interactions. * Output: volatile investor sentiment; upside tied to commercialization; downside amplifies if regulation stalls. **Concise Verdict:** * **Structural posture:** High-speculation frontier tech. Mixed signals—some execution upside, overshadowed by volatility and potential manipulation complexity. * **Action Guidance:** Recommended as a watchlist asset. Only consider small speculative position; require strict monitoring of FDA milestones and regulatory resolution.
Would love your analysis of the following: BTAI ATYR MDAI
Ok. I thought you were trading and missing out on profit. I will be buying as well. Just looking for a better entry point. I added 500 shares of MBOT and watching ATYR at the moment. There was some blood letting with ATYR, but nothing big.
aTyr ticker is not LIFE. It's ATYR
Still watching ATYR climbing ahead of Mid-September read out
MBOT, ATYR has a Phase 3 readout in September so in theory should run up a bit before hand. Looks promising but it’s a binary event - So do DD if you want to hold through it.
SRPT ATYR LION let's fucking go you unstable pieces of shit
SRPT had decent earnings Considering / ATYR is slowly climbing back up and MBOT is still waiting FDA device approval on Liberty so will keep an on eye on them. ATYR has a possible short squeeze going on if you look at numbers, so could be a bit spicy 😂
[https://www.reddit.com/r/ATYR\_Alpha/](https://www.reddit.com/r/ATYR_Alpha/)
Gemini suggests I tap the LIFE ticker. But there's no LIFE ticker, it's the Atyr Pharmaceutical company. From the Atyr ticker, Today I buy $100. They've set a stop loss of $3.50 per share and a take profit of $19.35. Since we're adventurous, today I buy what Gemini tells me: $100 in ATYR. From zero to hero, right?
ATYR PSTV also but that's taken off already so
So Martin is basically fooling everyone, by indirectly using Tweedle Call Sales to buy Puts on ATYR. And concocted that long essay write up, just to throw investors off guard, when there was no substance to his short thesis and he was only looking for a trade play?